AllRock Bio is focused on developing innovative therapies for cardiopulmonary diseases, particularly targeting conditions such as pulmonary hypertension and interstitial lung diseases. The company is advancing its lead program, ROC-101, which is an orally administered small molecule designed to inhibit both ROCK1 and ROCK2 isoforms. This dual inhibition is aimed at addressing the underlying pathophysiological processes associated with pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). ROC-101 has shown promising results in pre-clinical and early clinical trials, demonstrating its potential to reduce pulmonary arterial pressure and vascular resistance, thereby offering a novel therapeutic approach in a field where existing treatments have limited efficacy.

The development of ROC-101 is supported by a robust scientific framework that combines cutting-edge research with strategic partnerships. AllRock Bio emphasizes comprehensive clinical trial planning and execution, leveraging the extensive expertise of its leadership team, which includes professionals with significant experience in drug development and commercialization. The company aims to accelerate the delivery of life-saving therapies to patients by utilizing advanced scientific insights and a strong focus on regulatory compliance and clinical development strategies. This commitment to innovation and patient-centered care positions AllRock Bio as a key player in the biotech industry, particularly in the realm of cardiopulmonary therapeutics.

United States

We’re dedicated to advancing novel therapies to improve the lives of patients suffering from pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions

AllRock Bio

Company Details